$4.74
1.50% today
Nasdaq, Feb 05, 04:20 pm CET
ISIN
US28617K1016
Symbol
ELDN
Sector
Industry

Eledon Pharmaceuticals Inc Stock price

$4.67
+0.03 0.65% 1M
+1.98 73.61% 6M
+0.55 13.35% YTD
+2.92 166.86% 1Y
+0.88 23.22% 3Y
-4.51 49.13% 5Y
-1,991.17 99.77% 10Y
Nasdaq, Closing price Tue, Feb 04 2025
+0.21 4.71%
ISIN
US28617K1016
Symbol
ELDN
Sector
Industry

Key metrics

Market capitalization $278.98m
Enterprise Value $201.29m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio 2.53
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-56.22m
Free Cash Flow (TTM) Free Cash Flow $-37.42m
Cash position $78.19m
EPS (TTM) EPS $-5.71
Short interest 1.87%
Show more

Is Eledon Pharmaceuticals Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,821 stocks worldwide.

Eledon Pharmaceuticals Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

5 Analysts have issued a Eledon Pharmaceuticals Inc forecast:

5x Buy
100%

Analyst Opinions

5 Analysts have issued a Eledon Pharmaceuticals Inc forecast:

Buy
100%

Financial data from Eledon Pharmaceuticals Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
- -
-
100%
- Direct Costs 0.37 0.37
0% 0%
-
-0.37 -0.37
0% 0%
-
- Selling and Administrative Expenses 14 14
26% 26%
-
- Research and Development Expense 41 41
35% 35%
-
-56 -56
32% 32%
-
- Depreciation and Amortization 0.37 0.37
0% 0%
-
EBIT (Operating Income) EBIT -56 -56
32% 32%
-
Net Profit -100 -100
12% 12%
-

In millions USD.

Don't miss a Thing! We will send you all news about Eledon Pharmaceuticals Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Eledon Pharmaceuticals Inc Stock News

Neutral
GlobeNewsWire
7 days ago
IRVINE, Calif., Jan. 29, 2025 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today announced that David-Alexandre C.
Positive
Seeking Alpha
8 days ago
Eledon Pharmaceuticals' Tegoprubart, a second-gen anti-CD40L antibody, shows promise in preventing organ rejection without thromboembolic risks, addressing unmet needs in kidney and islet cell transplantation. Early trials indicate Tegoprubart's safety and efficacy, with no major side effects and better kidney function compared to current standards like tacrolimus. Eledon has a market cap of $2...
Neutral
GlobeNewsWire
23 days ago
Completed enrollment in Phase 2 BESTOW trial assessing tegoprubart in kidney transplantation four months ahead of schedule; on track to report topline results in fourth quarter of 2025 Presented updated data on 13 participants from ongoing Phase 1b trial that continue to support safety and tolerability of tegoprubart for prevention of organ rejection in kidney transplantation Announced positive...
More Eledon Pharmaceuticals Inc News

Company Profile

Eledon Pharmaceuticals, Inc. is a clinical stage biotechnology company using its expertise in targeting the CD40L pathway to develop potential treatments for people requiring an organ or cellular transplant, and for people living with autoimmune and neurodegenerative disease. The firm’s compound in development is AT-1501, a humanized IgG1 anti-CD40L antibody with high affinity for CD40 ligand (CD40L, also called CD154), a well-validated biological target with broad therapeutic potential. The CD40L/CD40 pathway is recognized for its prominent role in immune regulation, making it a candidate for therapeutic intervention in transplant tolerance, autoimmune disease, and neuro-inflammation. The company is building upon a deep historical understanding of the CD40/CD40L pathway, as well as preclinical and Phase 1 data, to initiate up to four phase 2 clinical studies with AT-1501. Eledon Pharmaceuticals was founded on March 26, 2004 and is headquartered in Irvine, CA.

Head office United States
CEO David-Alexandre Gros
Employees 20
Founded 2004
Website eledon.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today